Daily amylin replacement reverses hepatic glycogen depletion in insulin-treated streptozotocin diabetic rats.
In streptozotocin-diabetic rats treated with insulin replacement, liver glycogen is some 35% depleted. Five consecutive daily subcutaneous injections with amylin dose-dependently restored liver glycogen to normal levels. Significant increases over insulin-only therapy occurred with amylin doses of 10, 30 and 100 micrograms/day, representing amylin: insulin ratios of 0.22, 0.75 and 2.79.
Young
A A
AA
Department of Physiology, Amylin Corporation, San Diego, CA 92121.
Crocker
L B
LB
Wolfe-Lopez
D
D
Cooper
G J
GJ
D000682:Amyloid / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism*; D007328:Insulin / Q000627:therapeutic use*; D058228:Islet Amyloid Polypeptide; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains
D000682:Amyloid; D007328:Insulin; D058228:Islet Amyloid Polypeptide; D006003:Glycogen